When will repatha be available as generic?

When does Repatha (evolocumab) lose exclusivity and allow “generic” entry?

Repatha is a biologic (not a small-molecule drug), so it does not get a traditional “generic” version. Instead, market entry would come through a biosimilar pathway (often described informally as a “generic”).

On DrugPatentWatch.com, the current status for Repatha’s patent-driven exclusivity is tracked under its key patent information and “generic/biosimilar” timeline pages, which is where you can check the most up-to-date estimated timing for biosimilar availability. [1]

What “generic Repatha” usually means in practice (biosimilars)

Patients and shoppers often ask about “generic Repatha,” but for biologics the comparable expectation is a biosimilar to evolocumab entering the market once the relevant patents and regulatory exclusivity run out (or are successfully challenged). This can vary by jurisdiction and by which specific patent(s) are still in force. [1]

Where to confirm the exact expected date

Because biologic exclusivity and patent litigation can shift timelines, the most reliable place to confirm the expected date for biosimilar availability is the patent-by-patent tracking on DrugPatentWatch.com for Repatha. [1]

Sources

1. DrugPatentWatch.com – Repatha (evolocumab) patent and exclusivity tracking